Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company dedicated to developing antibody therapies for the treatment of inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), has completed Phase II clinical trials and is ready to advance into Phase III clinical trials for Glanzmann's thrombasthenia and Phase II clinical trials for Factor VII deficiency. Meanwhile, HMB-002 is currently in Phase I/II clinical trials for von Willebrand disease. The company focuses on developing preventive subcutaneous injection therapies for rare diseases with limited existing treatment options, while also advancing the research and development of preclinical candidates for other coagulation-related conditions.